Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $598.00 Price Target at Bank of America

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target lifted by equities research analysts at Bank of America from $571.00 to $598.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the pharmaceutical company’s stock. Bank of America‘s target price indicates a potential upside of 18.68% from the company’s previous close.

A number of other brokerages have also recently commented on VRTX. Evercore increased their price target on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Jefferies Financial Group started coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday. They set a “buy” rating and a $580.00 price objective on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $570.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Citigroup lifted their price target on Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Scotiabank boosted their price target on Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an “outperform” rating in a research report on Friday, February 13th. Twenty-three investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $550.59.

Vertex Pharmaceuticals Trading Up 9.3%

Shares of NASDAQ VRTX traded up $43.03 during midday trading on Tuesday, reaching $503.90. The company’s stock had a trading volume of 1,415,798 shares, compared to its average volume of 1,467,100. Vertex Pharmaceuticals has a fifty-two week low of $362.50 and a fifty-two week high of $519.68. The stock has a market capitalization of $128.00 billion, a price-to-earnings ratio of 32.97 and a beta of 0.31. The stock has a 50 day simple moving average of $467.50 and a 200-day simple moving average of $435.79.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.98 EPS. As a group, equities analysts anticipate that Vertex Pharmaceuticals will post 15.63 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Mark E. Bunnage sold 620 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $301,537.00. Following the transaction, the executive vice president owned 7,284 shares in the company, valued at approximately $3,542,573.40. The trade was a 7.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jonathan Biller sold 945 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total transaction of $459,600.75. Following the transaction, the executive vice president directly owned 13,659 shares of the company’s stock, valued at $6,643,054.65. This represents a 6.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 91,156 shares of company stock worth $42,845,497 over the last three months. 0.20% of the stock is owned by corporate insiders.

Institutional Trading of Vertex Pharmaceuticals

Large investors have recently made changes to their positions in the company. Police & Firemen s Retirement System of New Jersey lifted its holdings in Vertex Pharmaceuticals by 3.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company’s stock worth $17,378,000 after purchasing an additional 1,393 shares in the last quarter. Bailard Inc. grew its holdings in Vertex Pharmaceuticals by 0.5% during the 2nd quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company’s stock valued at $16,983,000 after buying an additional 200 shares in the last quarter. Leuthold Group LLC bought a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at about $5,030,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Vertex Pharmaceuticals by 3.8% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 544,978 shares of the pharmaceutical company’s stock worth $213,435,000 after buying an additional 20,053 shares in the last quarter. Finally, Advisory Resource Group purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter worth about $1,286,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Povetacicept RAINIER interim analysis met primary and all secondary endpoints, showing meaningful benefit in IgA nephropathy — a potential new commercial franchise that could diversify Vertex’s revenue stream. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: Major analysts raised targets or initiated coverage after the results: Oppenheimer to $600 (Outperform), Jefferies initiated Buy at $580, HC Wainwright raised target to $641, and BMO/William Blair reaffirmed bullish views — signaling increased street confidence in upside from povetacicept and longer-term cash flows. Analyst Coverage & Price Target Moves
• Neutral Sentiment: News and market commentary noted Vertex as a premarket leader and discussed valuation after the move; these pieces provide context for momentum but don’t add new clinical or commercial data. S&P 500 Futures Steady; Vertex Leads
• Neutral Sentiment: Coverage discussing whether the stock remains fairly valued after recent moves may temper near-term upside if investors reassess multiples versus delivery timelines for a new kidney franchise. Is Vertex Still Fairly Priced?
• Negative Sentiment: Recent quarterly results showed only a tiny EPS miss (Feb quarter: $5.03 vs. $5.05 expected) — a reminder that CF franchise growth and near-term financials still matter while new-kidney commercialization timelines, regulatory reviews and competitive dynamics (other IgAN programs) present execution risk.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.